While prostate serum PSA screening has improved marginally in lowering the risk of death due to prostate cancer over a decade in a decade [3], its lack of specificity and sensitivity to factors such as age reduces its effectiveness as an indicator [4]. The gene discussed is KLK3; the disease is prostate carcinoma.